
About Aardark Therapeutics
Aardark Therapeutics is a publicly listed company based in San Diego (United States) founded in 2017. Small molecule therapeutics for obesity and metabolic disorders are developed. Aardark Therapeutics has raised $138 million across 4 funding rounds from investors including Sorrento Therapeutics, Cantor and Tetragon. The company has 22 employees. Its chief executive, as recorded, is Tien Lee. Aardark Therapeutics offers products and services including ARD-101. Its focus areas include Life Sciences, Obesity and Drugs. Its legal entity is AARDVARK THERAPEUTICS, INC. Its competitors include Altimmune, Carmot and BioAge Labs; 3 of its 3 listed competitors have raised funding.
Company details
Provider of small molecules therapeutics for treating obesity and rare genetic metabolic disorders. Their lead candidate, ARD-101 is an oral composition that selectively disrupts hunger signaling and regulates energy homeostasis. The candidate helps through increasing metabolic rate, interfering with nutrient absorption, or directly modifying CNS pathways, all of which are related to undesirable off-target effects.
- Headquarters San Diego, United States
- Employees 22
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website aardvarktherapeutics.com
- Social LinkedIn Facebook Instagram
- Legal Name Aardvark Therapeutics, Inc.
- Net Profit-$57.59 M (USD)-179.73as on Dec 31, 2025
- EBITDA-$62.69 M (USD)-175.33as on Dec 31, 2025
- Total Equity Funding$138M (USD)
in 4 rounds
- Latest Funding Round$85M (USD), Series C
May 2024
- InvestorsSorrento Therapeutics
& 16 more
- Employee Count22
Products & Services of Aardark Therapeutics
Aardark Therapeutics offers a comprehensive portfolio of products and services, including ARD-101.
Oral drug activating receptors to suppress hunger for rare diseases
Funding Insights of Aardark Therapeutics
Aardark Therapeutics has successfully raised a total of $138M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $85 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $138M
- Total Rounds 4
- Last Round Series C β $85M
- First Round $9M
(May 2019)
- Investors Count 17
All 4 funding rounds of Aardark Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | $85M | Series C | β | Decheng Capital | |
| Jun 2021 | $29M | Series B | β | Sorrento Therapeutics | |
| Nov 2019 | $15M | Series A | β | Vickers Venture Partners, Premier Partners | |
| May 2019 | $9M | Series A | β | β | β |
17 investors in total: 17 institutional.
Investors in Aardark Therapeutics
Aardark Therapeutics has secured backing from 17 investors, including venture fund and institutional investors. Prominent investors backing the company include Sorrento Therapeutics, Cantor and Tetragon.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on life science and technology sectors | decheng.com | Shanghai, China | ||
Investments in healthcare companies are made by SymBiosis. | symbiosis.vc | Bentonville, United States | ||
Investment in early-stage companies across AI, biotech, and cleantech sectors with access to global resources. | lgtechventures.com | |||
Growth-stage venture capital is invested in Singapore and China. | vickersventure.com | Singapore, Singapore | ||
Private equity & venture capital firm | premierpartners.co.kr | Seoul, South Korea | ||
| bnhinv.com | ||||
Venture capital fund focused on tech startups | koreaomega.co.kr | Seoul, South Korea | ||
Manages diversified investment portfolios across various asset classes. | 1997 | cormorant.com | Boston, United States | |
Diversified investment management services are offered across multiple asset classes. | 2005 | tetragoninv.com | New York, United States |
Investor details for Aardark Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aardark Therapeutics
20 people are tracked at Aardark Therapeutics (7 in leadership, 11 in board & advisors, 2 in team); the tracked headcount is 22.
| Name | Role | Group |
|---|---|---|
Tien Lee | CEO | Leadership |
Andreas Niethammer | Chief Medical Officer | Leadership |
Bryan Jones | COO | Leadership |
Shital Kalariya | Senior Medical Director | Leadership |
Nelson Sun | CFO | Leadership |
Danny Villeneuve | Chief Commercial Officer (cco) | Leadership |
Manasi Sinha Jaiman | Chief Medical Officer | Leadership |
Jeffrey Chi | Director | Board & advisors |
Stephen V. Faraone | Advisor | Board & advisors |
Larry Cheskin | Advisor | Board & advisors |
Zachary Hornby | Director | Board & advisors |
Jerold Chun | Advisor | Board & advisors |
Henry Ji | Director | Board & advisors |
Ralph A. DeFronzo | Advisor | Board & advisors |
Jerel A. Banks | Director | Board & advisors |
Sheila Gujrathi | Advisor | Board & advisors |
Kim Janda | Advisor | Board & advisors |
Rohit Loomba | Advisor | Board & advisors |
Emily Arsenault | Finance & Accounting Consultant | Team |
Jeff Oster | General Counsel | Team |
Complete people profiles for Aardark Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Aardark Therapeutics
Aardark Therapeutics is a publicly listed company on the NASDAQ with ticker symbol AARD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date13 Feb 2025
- Listed onNASDAQ: AARD
- Listed entityAardvark Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS0029421007
- Share price$4.04 (-9.21% on the day) · 2026-10-13
- Market capitalisation$88.4M
- EPS (diluted, trailing year)$-3.21
- Volume (last session)218,304
Financials of Aardark Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$57.6M | -$62.7M | |
| 2024 | -$20.6M | -$22.8M | |
| 2023 | -$7.2M | -$7.3M | |
| 2022 | -$13.6M | -$11.2M |
Detailed financial statements for Aardark Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Aardark Therapeutics
4 dated milestones of Aardark Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Aardark Therapeutics is founded.
- Funding First funding round of $9.0M.
- Funding Latest funding round, Series C, of $85.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Aardark Therapeutics
Aardark Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Altimmune, Carmot and BioAge Labs.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| altimmune.com | 1997 | Gaithersburg, United States | $58M | 17 | Vaccines for infectious diseases and solid tumors are developed. | |
| carmot.us | 2008 | Berkeley, United States | $385.52M | Disease-modifying therapies for metabolic diseases are developed. | ||
| bioagelabs.com | 2015 | Vallejo, United States | $293.9M | 43 | Bioinformatics platform is provided for biomarkers and drug discovery. |
Detailed competitors of Aardark Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Aardark Therapeutics
The website of Aardark Therapeutics (aardvarktherapeutics.com) receives about 5.7K visits a month.
- Monthly visits5.7K
▲ 40.8% vs previous month
Websites whose visitors overlap most with Aardark Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| truvianhealth.com | 100% | 4.2K | #4,492,336 | View details | |
| latitudepharma.com | 100% | 680.7K | View details | ||
| carihealth.com | 99% | View details | |||
| clinicomp.com | 98% | #523,501 | View details | ||
| ambrx.com | 98% | 1.7K | #3,844,291 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 21 similar websites and full traffic analytics for Aardark Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 21 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Obesity
3 companies that operate in the same segment as Aardark Therapeutics (Obesity) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Bioinformatics platform is provided for biomarkers and drug discovery. | 2015 | Vallejo, California, United States | USD 293.9 M | USD 8.99 M | 64 | |
Disease-modifying therapies for metabolic diseases are developed. | 2008 | Berkeley, California, United States | USD 385.52 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aardark Therapeutics
Complete news archive for Aardark Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aardark Therapeutics
Aardark Therapeutics was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Aardark Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Tien Lee is the CEO of Aardark Therapeutics, as recorded in our data.
Aardark Therapeutics is a funded company, having raised a total of $138M across 4 funding rounds to date. The company's 1st funding round was a Series A of $9M, raised on May 2019.
Aardark Therapeutics has 22 employees.
Provider of small molecules therapeutics for treating obesity and rare genetic metabolic disorders. Their lead candidate, ARD-101 is an oral composition that selectively disrupts hunger signaling and regulates energy homeostasis. The candidate helps through increasing metabolic rate, interfering with nutrient absorption, or directly modifying CNS pathways, all of which are related to undesirable off-target effects.
Aardark Therapeutics's top competitors include BioAge Labs, Carmot and Altimmune.
Aardark Therapeutics offers ARD-101.
Yes, Aardark Therapeutics is publicly traded on NASDAQ under the ticker symbol AARD.
Aardark Therapeutics has 17 investors. Key investors include Sorrento Therapeutics, Cantor, Tetragon, Decheng Capital, and Cormorant.
Aardark Therapeutics operates through Aardvark Therapeutics, Inc..
